Compounded, Gray market and Counterfeit Semaglutide

What regulators have documented about semaglutide obtained outside the approved supply chain.

Read this first

This page is not built on clinical trial evidence. There are no randomised trials of compounded, gray market or counterfeit semaglutide, because these products are not standardised and are not studied. What exists instead is a regulatory and enforcement record: FDA alerts, WHO product alerts, adverse event reports and manufacturer statements. That is a weaker class of evidence than the trial data on the research-backed semaglutide page by Onpeps.

Compounded semaglutide

What is compounded semaglutide?

Compounded semaglutide is prepared by a pharmacy rather than by the drug's manufacturer.

The FDA's position is direct: compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness, or quality before they are marketed. The agency states that a compounded drug might be appropriate if a patient's medical need cannot be met by an FDA-approved drug, or where the approved drug is not commercially available.1

What is the difference between compounded and generic semaglutide?

A generic is an approved copy. It must demonstrate equivalence to the branded drug, and it passes through FDA review.

A compounded product is prepared by a pharmacy and receives no such review. The two words are often used interchangeably in marketing. They describe entirely different regulatory categories.

Is compounded semaglutide as effective as branded Wegovy?

No trial has compared them. Compounded products are not standardised between pharmacies, so there is no single product to test.

What is on record is that the FDA does not review these products for effectiveness, and that the agency has documented fraudulent compounded semaglutide and tirzepatide carrying false label information, including labels naming compounding pharmacies that do not exist and labels naming licensed pharmacies that did not make the product.1

Anyone claiming a compounded product performs equivalently to Wegovy is not citing evidence, because none exists.

What is semaglutide acetate, and why does it matter?

Semaglutide acetate and semaglutide sodium are salt forms.

The FDA states these salt forms are different active ingredients than those used in the approved drugs, that the agency does not have information on whether they share the same chemical and pharmacologic properties as the approved active ingredient, and that it is not aware of any lawful basis for their use in compounding.1

A product sold as a semaglutide salt is therefore not the same ingredient as the approved drug, on the regulator's own reading.

How many adverse events have been reported?

As of 31 May 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide, and more than 730 associated with compounded tirzepatide.1

The agency adds an important qualifier. Federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to the FDA, so adverse events from compounded versions are likely underreported. The agency also notes that many reported events appear consistent with those seen with the approved products.1

What has gone wrong with dosing?

Two distinct failure modes appear in the FDA record.

The first is measurement error. The agency has received multiple reports of adverse events, some requiring hospitalisation, that may relate to dosing errors with compounded injectable semaglutide. These arose from patients measuring and self-administering incorrect doses, and in some cases from health care professionals miscalculating doses.1

The second is exceeding the approved label. The FDA has received reports that may relate to people prescribed compounded products at doses beyond the approved label, whether by using more product per dose, dosing more frequently, or escalating faster. Some of these adverse events were serious, and patients reported seeking medical attention for nausea, vomiting, diarrhoea, abdominal pain and constipation.1

Telehealth and compounding pharmacies

What warning signs does the FDA list?

The agency publishes a specific list of telehealth red flags. A company is a concern if it:

• claims the compounded drug is the same as an FDA-approved drug

• offers medicine at deep discounts or prices that seem too good to be true

• sends medicine that looks different from what you previously received or was pictured, or arrives in broken or damaged packaging, or lacks instructions for use

• does not require screening and a prescription by a licensed doctor before providing medicine

• does not have a licensed doctor available to answer questions after you receive the medication

• makes spelling errors on the label or provides incorrect pharmacy addresses

• includes a pharmacy name on the label that you think might be fraudulent

This list is the FDA's, reproduced because it is the only authoritative vetting checklist in circulation.1

What does the FDA tell patients to do instead?

Obtain a prescription from a doctor and fill it at a state-licensed pharmacy. Use compounded drugs only where medical needs cannot be met by an FDA-approved drug. Contact the compounder or telehealth platform with questions about the label or instructions for use.1

Gray market and research-use-only vials

What does "research use only" actually mean?

As a legal shield for the seller, less than the label implies.

The FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide labelled "for research purposes" or "not for human consumption." The agency's stated basis is that these products were sold directly to consumers for human use, with dosing instructions supplied. The FDA urges consumers not to purchase them, describing them as of unknown quality and potentially harmful.1

The label describes a paperwork position. It does not describe how the product is being sold or used, and the regulator has said so.

What is the FDA doing at the border?

The agency has established a green list import alert, 66-80, to stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the US supply chain. The alert does not apply to API from manufacturers found compliant on inspection, and the FDA states it does not create new limits on legal compounding.1

Can retatrutide or cagrilintide be compounded or stacked legally?

No. The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, that they are not components of FDA-approved drugs, and that they have not been found safe and effective for any condition.1

The agency has issued warnings to telehealth companies marketing unapproved drugs such as retatrutide including direct-to-consumer marketing, to API distributors selling retatrutide and other GLP-1 drugs to compounders, and to outsourcing facilities repackaging retatrutide.1

On stacking generally: no randomised trial has tested combinations assembled outside a clinical programme. There is no safety dataset to consult, which means claims about stack safety in either direction are unsupported. Absence of reported harm is not evidence of safety.

What about product arriving warm?

Injectable GLP-1 drugs require refrigeration as stated in their package inserts. The FDA has received complaints that certain compounded GLP-1 drugs arrived warm or with inadequate ice packs, and recommends that patients do not use any injectable GLP-1 drug that arrives warm or insufficiently refrigerated, because this can affect quality.1

What is bacteriostatic water?

Bacteriostatic water is sterile water containing a preservative, usually benzyl alcohol, which inhibits bacterial growth and allows a vial to be entered more than once. Plain sterile water contains no preservative and is intended for single use.

That is the definition. Reconstitution volumes and unit conversions are covered in the ONPEPS dosing guides.

Certificates of analysis and testing

What is a Certificate of Analysis?

A COA is a document reporting laboratory results for a specific batch, typically identity and purity.

Two limits matter. A COA describes the batch that was tested, not necessarily the vial in hand. And a COA is only as reliable as the chain of custody between the lab, the seller, and the buyer, which an end purchaser cannot independently verify.

What is the difference between HPLC purity and mass spectrometry identity?

They answer different questions. Purity testing by high-performance liquid chromatography estimates how much of the sample is the intended compound versus everything else. Mass spectrometry confirms whether the molecule present is the molecule claimed.

A sample can be high purity and still be the wrong compound. A COA reporting purity alone does not establish identity.

Can a COA be faked or recycled?

A COA is a PDF. Nothing about the format prevents reuse across batches or fabrication outright.

The relevant regulatory context is that the FDA has documented fraudulent compounded products whose labels named pharmacies that do not exist, and labels naming licensed pharmacies that did not compound the product.1 Where labels have been fabricated, treating accompanying documents as self-verifying is not defensible.

Counterfeits

What has the WHO documented?

The WHO issued a medical product alert covering three falsified batches of Ozempic, detected in Brazil in October 2023, the United Kingdom in October 2023 and the United States in December 2023. Its Global Surveillance and Monitoring System had been recording increased reports of falsified semaglutide across all geographical regions since 2022, and this was the first official notice issued after confirmation of some of those reports.2

What happens if a falsified product is injected?

The WHO describes two failure modes. If the product lacks the necessary raw components, the result can be complications from unmanaged blood glucose or weight. In other cases, an undeclared active ingredient may be present in the injection device, insulin being the example the WHO gives, producing an unpredictable range of health risks.2

The FDA states counterfeit drugs may contain the wrong ingredients, too little or too much active ingredient, none at all, or other harmful ingredients.1

The insulin scenario is the one that turns a fake into an emergency. It is also the reason "it did nothing" is not the worst outcome available.

What does the WHO advise?

Buy medicines with prescriptions from licensed physicians. Avoid unfamiliar or unverified sources, including online. Check packaging and expiry dates. Store injectable semaglutide in the refrigerator. Notifications of falsified medicines can be sent to the WHO at rapidalert@who.int.2

How do I report a problem?

The manufacturer's position

Novo Nordisk, announcing a US list price reduction on 24 February 2026, stated that with the supply of all doses fully available nationwide in the US, there is no reason for patients to gamble with their health with knock-off products produced by compounders.3

This is recorded as what the manufacturer said. Novo Nordisk holds a commercial interest in the compounding question, and that context belongs alongside the quote.

What is not known

Several widely circulated figures about gray market purity cannot be traced to a verifiable primary source. Where a purity percentage is quoted without a named laboratory, sample count and methodology, it should be treated as unverified regardless of how often it is repeated.

There is no published study establishing what proportion of gray market semaglutide is accurately labelled. There is no registry of outcomes among people self-sourcing. The FDA's adverse event counts cover compounded products and are, by the agency's own statement, an undercount.1

The honest summary is that nobody, including regulators, knows the true denominator. Risk estimates in either direction are not measurements.

Sources

1. US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug Alerts and Statements. Content current as of 15 June 2026. Adverse event counts stated as of 31 May 2026. fda.gov

2. World Health Organization. WHO issues warning on falsified medicines used for diabetes treatment and weight loss. 20 June 2024. who.int

3. Novo Nordisk Inc. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus. 24 February 2026. prnewswire.com

Not medical advice

If you are currently using a product obtained outside a pharmacy, the route back to clinical oversight is a licensed prescriber who knows what you have taken.

Regulatory sources verified August 4, 2026. Compounding law and enforcement status change frequently. Re-verify before relying on any statement here.